Patents Assigned to The University of Arkansas For Medical Sciences
-
Publication number: 20160354150Abstract: A device and method of using the device to detect the presence and composition of clots and other target objects in a circulatory vessel of a living subject is described. In particular, devices and methods of detecting the presence and composition of clots and other target objects in a circulatory vessel of a living subject using in vivo photoacoustic flow cytometry techniques is described.Type: ApplicationFiled: August 18, 2016Publication date: December 8, 2016Applicant: University of Arkansas for Medical SciencesInventors: Vladimir Pavlovich Zharov, Ekaterina Galanzha
-
Publication number: 20130052158Abstract: The present disclosure provides methods for treating multiple myeloma using autologous expanded and activated NK cells.Type: ApplicationFiled: October 30, 2009Publication date: February 28, 2013Applicant: University of Arkansas for Medical ScienceInventor: Frits Van Rhee
-
Publication number: 20100204254Abstract: The present invention discloses statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) consistently and significantly increased endothelial cell thrombomodulin protein and functional activity. Statins also abrogated the downregulation of thrombomodulin that occurs in response to radiation injury. These results indicate that preserving or restoring endothelial thrombomodulin expression and function by statins may be useful in a variety of disorders associated with widespread endothelial dysfunction such as sepsis, adult respiratory distress syndrome, and normal tissue radiation injury.Type: ApplicationFiled: January 29, 2010Publication date: August 12, 2010Applicant: The University of Arkansas for Medical SciencesInventors: Martin K. Hauer-Jensen, Louis M. Fink, Jawahar Lal Mehta, Junru Wang, Jacob Joseph
-
Patent number: 7638277Abstract: The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment by utilizing the DNA and/or protein disclosed herein.Type: GrantFiled: April 7, 2006Date of Patent: December 29, 2009Assignee: The University of Arkansas for Medical SciencesInventors: Timothy J. O'Brien, Lowell J. Underwood
-
Patent number: 7459437Abstract: To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ?3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.Type: GrantFiled: December 4, 2003Date of Patent: December 2, 2008Assignee: University of Arkansas for Medical SciencesInventor: John D. Shaughnessy
-
Publication number: 20080095768Abstract: Methods for treating MM using anti-CS1 antibodies are provided herein.Type: ApplicationFiled: August 7, 2007Publication date: April 24, 2008Applicants: PDL BIOPHARMA, INC., UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCEInventors: Daniel AFAR, Frits VAN RHEE
-
Patent number: 7335351Abstract: The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.Type: GrantFiled: April 23, 2004Date of Patent: February 26, 2008Assignee: The University of Arkansas for Medical SciencesInventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin
-
Patent number: 7306927Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and their presence may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.Type: GrantFiled: July 13, 2001Date of Patent: December 11, 2007Assignee: The University of Arkansas for Medical SciencesInventor: Timothy I. O'Brien
-
Patent number: 7308364Abstract: Gene expression profiling between normal B cells/plasma cells and multiple myeloma cells revealed four distinct subgroups of multiple myeloma plasma cells that have significant correlation with clinical characteristics known to be associated with poor prognosis. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognostics for the four subgroups of multiple myeloma based on the expression of 24 genes were also established. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. The development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.Type: GrantFiled: June 4, 2003Date of Patent: December 11, 2007Assignee: The University of Arkansas for Medical SciencesInventors: John D. Shaughnessy, Fenghuang Zhan, Bart Barlogie
-
Patent number: 7291462Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.Type: GrantFiled: June 20, 2003Date of Patent: November 6, 2007Assignee: The University of Arkansas for Medical SciencesInventors: Timothy J. O'Brien, Hirotoshi Tanimoto
-
Patent number: 7282198Abstract: The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.Type: GrantFiled: February 21, 2003Date of Patent: October 16, 2007Assignee: The University of Arkansas for Medical SciencesInventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin
-
Patent number: 7202348Abstract: The present invention provides synthetic immunochemical haptens for the generation of antibodies that are designed to recognize the common molecular features of d-methamphetamine-like abused stimulants with insignificant cross-reactivity to endogenous substrates (e.g. dopamine) or over-the-counter medications (e.g. 1-methamphetamine, pseudoephedrine, phenylpropanolamine and ephedrine). These monoclonal antibodies and their antigen binding fragments are useful in treatment plans for recovering addicts, in emergency room settings for rapidly reversing a drug overdose, in protection of fetuses from drug-abusing pregnant mothers or in a psychiatric setting to reduce the exacerbation of psychotic disorders caused by stimulant drugs.Type: GrantFiled: September 26, 2002Date of Patent: April 10, 2007Assignee: The University of Arkansas for Medical SciencesInventors: Samuel M. Owens, Frank Ivy Carroll, Philip Abraham
-
Patent number: 7183383Abstract: The present invention provides a method of recovering cellular functions in cells following injury, comprising the step of contacting said cells with collagen IV or a natural or mutated fragment thereof. Further provided is a pharmaceutical composition, comprising a therapeutically effective amount of collagen IV or a natural or mutated fragment thereof and a topically acceptable carrier.Type: GrantFiled: March 20, 2003Date of Patent: February 27, 2007Assignee: The University of Arkansas for Medical SciencesInventors: Ricky Gene Schnellmann, Paul A. Nony
-
Patent number: 7067250Abstract: The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.Type: GrantFiled: August 21, 1998Date of Patent: June 27, 2006Assignee: The University of Arkansas for Medical SciencesInventors: Lowell J. Underwood, Timothy J. O'Brien
-
Patent number: 7034020Abstract: The present invention provides a series of compounds having structural formulas wherein n1 is 1 to 5, n2 is 1 to 4 and m is 1 to 3; X is O or NH; Y is CH2, O, S, NH, NR; R is selected from the group consisting a straight-chain aliphatic group, a branched-chain aliphatic group and an alicyclic group; wherein R? is selected from the group consisting of hydrogen, methyl and ethyl; when Y is O, n1 is not 1; and wherein X and R? are independently optionally substituted at C2, C3 or C4 in compounds of Fomula IV or a pharmaceutically acceptable salt thereof. Also provided is a method of inactivating antigen-specific T cells in a n individual.Type: GrantFiled: December 12, 2003Date of Patent: April 25, 2006Assignee: The University of Arkansas for Medical ScienceInventors: Kathleen Gilbert, E. Kim Fifer
-
Patent number: 6978788Abstract: The present invention provides a minimally invasive, comprehensive same-day diagnosis and treatment method to remove tumor and ablate margins in breast cancer patients, comprising disease diagnosis by MRI and touch preparation cytology, followed by tumor removal and ablation of tumor margins.Type: GrantFiled: November 27, 2002Date of Patent: December 27, 2005Assignee: The University of Arkansas for Medical ScienceInventors: V. Suzanne Klimberg, Steven Harms, Soheila Korourian
-
Patent number: 6875609Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. Specifically, the present invention relates to expression of hepsin protease. The detected proteases are themselves specifically over-expressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.Type: GrantFiled: March 20, 2002Date of Patent: April 5, 2005Assignee: The University of Arkansas For Medical SciencesInventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin
-
Publication number: 20040127564Abstract: The present invention provides a series of compounds having structural formulas 1Type: ApplicationFiled: December 12, 2003Publication date: July 1, 2004Applicant: The University of Arkansas for Medical SciencesInventors: Kathleen Gilbert, E. Kim Fifer
-
Patent number: 6642013Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.Type: GrantFiled: July 18, 2000Date of Patent: November 4, 2003Assignee: The University of Arkansas for Medical SciencesInventors: Timothy J. O'Brien, Lowell J. Underwood
-
Publication number: 20030027144Abstract: The present invention provides a DNA encoding a TADG-16 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-16 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-16 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-16 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell.Type: ApplicationFiled: July 17, 2001Publication date: February 6, 2003Applicant: The University of Arkansas for Medical SciencesInventors: Lowell J. Underwood, Timothy J. O'Brien, Kazushi Shigemasa